A nationwide recall of certain compounded tirzepatide injections in the United States has highlighted patient safety concerns related to injectable medication sterility and dosing accuracy. Apothecary Pharma LLC initiated a voluntary recall on September 24, 2026, after it could not assure the sterility of certain products. The US Food and Drug Administration (FDA) classified the recall as Class II on October 10, indicating that exposure could cause temporary or medically reversible health consequences.

According to the supplied report, the recall involves 22 lot codes of tirzepatide injections at a concentration of 18 mg/mL, packaged in 4 mL multidose vials. The recall does not cover all GLP-1 medicines, and the sterility concern does not establish that every affected vial is contaminated. Healthcare professionals and patients should consult official recall information to verify…